While FDA recently approved ibrutinib (Imbruvica, Janssen Biotech, Inc. and Pharmacyclics LLC) to treat patients with chronic lymphocytic leukemia (CLL), United Kingdom’s National Institute of Health and Care Excellence (NICE) will not yet recommend the medication.
New data from Novo Nordisk will help its Victoza (liraglutide) for type 2 diabetes better compete against Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin). Victoza significantly reduced the combined incidence of heart attack, stroke and cardiovascular death in high-risk Type 2 diabetes patients, according to Novo Nordisk
Prior authorizations are here to stay. Are yours working against you? Find out.
While many Americans and legislators have complained about the rising cost of medications in recent years, seniors are likely impacted more than the population at large. The average retail price among 622 prescription medications widely used by seniors doubled from 2006 to 2013, to reach more than $11,000, according to the American Association of Retired Persons’ (AARP)’s updated “Rx Price Watch” report.
Model set to improve compliance, reduce costs, but reimbursement challenges remain.
Factors include rising costs of brand medications, increased specialty therapy use
Highlights include Medicaid specialty drug reimbursement, managing ICD-10 implementation
Shared resources, specialized drugs key to curbing costs
How one $1.62 billion healthcare network uses global sourcing to simultaneously improve quality and wring costs out of its purchasing program and supply chain.
A clinical staff armed with the best clinical decision support (CDS) tools can be a game changer when it comes to improving care quality and reducing care costs.
Rob Danoff, DO, of Aria Health System, explains what should be done to reduce health management costs, while improving care of diabetic patients.
Stroke patients were more adherent to mail order prescriptions versus picking up their medications at retail pharmacies, according to new research presented at the recent International Stroke Conference in Los Angeles, Calif.
Cost issues work their way into medical school curricula
FDA has approved tofacitinib citrate extended-release (Xeljanz XR, Pfizer) tablets for the treatment of moderate to severe rheumatoid arthritis (RA).
FDA approved obinutuzumab (Gazyva, Genentech) for the treatment of certain patients with follicular lymphoma. Here are the top 5 things to know about Gazyva.
Considering entering into a risk-sharing agreement with another payer or provider? Avoid these top mistakes.
In this Q&A, experts discuss how emerging treatments and technologies are affecting diabetes costs.
While there are rumors that President Barack Obama could use his executive authority to regulate drug pricing, analysts say that is not likely. Experts also say that the presidential candidates’ plans to reform skyrocketing drug prices won’t work.
New research suggests that mail-order pharmacies may help stroke survivors take their meds.
Analysis finds scientific validation of personalized medicine’s ability to improve patient outcomes.
Making the healthcare experience more convenient, effective, and less expensive.
: Proactive pharma tools help CVS manage pharmacy costs and focus on ensuring patients have access to the right drugs at the lowest cost.
A quick progress report on efforts to improve price transparency in the United States, as well as some state-by-state information.
Seniors who regularly took leading heartburn drugs such as Nexium, Prilosec and Prevacid (Takeda Pharmaceuticals) were 44% more likely to end up with dementia, according to a new study.
In one of the biggest drug pricing settlements in history, Pfizer is paying $784.6 million to settle claims alleging that the practices of its Wyeth subsidiary relating to the calculation of Medicaid rebates for Protonix (pantoprazole sodium) violated the Federal Civil False Claims Act and other laws.
Before it hits you, take time to consider effective benefit strategies
FDA has granted breakthrough therapy designation for durvalumab (MEDI4736, AstraZeneca) for the treatment of urothelial bladder cancer.
FDA has approved brivaracetam (Briviact, UCB, Inc.) as an add-on therapy for the treatment of partial onset-seizures in patients with epilepsy.
FDA issued a new guidance recommending that individuals who have been to areas with active Zika virus transmission, who have potentially have been exposed to the virus, or have had a confirmed Zika virus infection should not donate blood. Here are the other top 5 things to know about FDA's new guidelines on Zika blood transmissions.
